Last reviewed · How we verify

Dexamethasone given orally — Competitive Intelligence Brief

Dexamethasone given orally (Dexamethasone given orally) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucocorticoid (corticosteroid). Area: Immunology, Rheumatology, Oncology (supportive care), Endocrinology.

phase 3 Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR) Immunology, Rheumatology, Oncology (supportive care), Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Dexamethasone given orally (Dexamethasone given orally) — Hoffmann-La Roche. Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dexamethasone given orally TARGET Dexamethasone given orally Hoffmann-La Roche phase 3 Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR)
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) marketed Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Prelone prednisolone Generic (originally Schering) marketed Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Methylprednisolone Injectable Product Methylprednisolone Injectable Product Vanderbilt University Medical Center marketed Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR)
Dexamethasone low dose Dexamethasone low dose Manuel Taboada Muñiz marketed Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR)
Dexamethasone IV for PO Dexamethasone IV for PO Vanderbilt University Medical Center marketed Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR)
Dexamethasone (IV) Dexamethasone (IV) Cancer Trials Ireland marketed Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucocorticoid (corticosteroid) class)

  1. Merck Sharp & Dohme LLC · 2 drugs in this class
  2. The Children's Hospital of Zhejiang University School of Medicine · 2 drugs in this class
  3. Vanderbilt University Medical Center · 2 drugs in this class
  4. Fujian Shengdi Pharmaceutical Co., Ltd. · 1 drug in this class
  5. Hamad Medical Corporation · 1 drug in this class
  6. Hoffmann-La Roche · 1 drug in this class
  7. Generic (originally Upjohn/Pfizer) · 1 drug in this class
  8. Manuel Taboada Muñiz · 1 drug in this class
  9. Masonic Cancer Center, University of Minnesota · 1 drug in this class
  10. Hospital for Special Surgery, New York · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexamethasone given orally — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-given-orally. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: